Department of Pediatric Gastroenterology, University of California San Diego (UCSD), and Rady Children's Hospital, San Diego, California.
Department of Pharmacology, University of Valencia and FISABIO-University Hospital Dr. Peset, School of Medicine, Valencia, Spain.
Semin Liver Dis. 2017 May;37(2):119-127. doi: 10.1055/s-0037-1601350. Epub 2017 May 31.
Cell death and inflammation are two central elements in the development of liver fibrosis. Inflammasomes are intracellular multiprotein complexes expressed in both hepatocytes and nonparenchymal cells in the liver that are key regulators of inflammation and cell fate. They respond to cellular danger signals by activating caspase 1, releasing the proinflammatory cytokines IL-1β and IL-18, as well as initiating a novel pathway of programmed cell death termed "pyroptosis." These processes can initiate and perpetuate an abnormal wound-healing response with the principle cellular target being the activation of hepatic stellate cells. From the various inflammasomes, the NLRP3 inflammasome has been increasingly implicated in the pathogenesis of chronic inflammatory liver diseases, including nonalcoholic steatohepatitis, a disease process that is soaring and has evolved as a primary cause of liver fibrosis and need for liver transplantation. In this review, the authors highlight the growing evidence for both indirect and direct effects of inflammasomes in triggering liver fibrosis as well as potential novel targets for antifibrotic therapies.
细胞死亡和炎症是肝纤维化发展的两个核心要素。炎性小体是在肝细胞和肝非实质细胞中表达的细胞内多蛋白复合物,是炎症和细胞命运的关键调节剂。它们通过激活半胱天冬酶 1 对细胞危险信号作出反应,释放促炎细胞因子 IL-1β 和 IL-18,并启动一种称为“细胞焦亡”的程序性细胞死亡的新途径。这些过程可以引发和持续异常的伤口愈合反应,主要的细胞靶标是肝星状细胞的激活。在各种炎性小体中,NLRP3 炎性小体越来越多地与慢性炎症性肝病的发病机制有关,包括非酒精性脂肪性肝炎,这一疾病过程正在飙升,并已演变为肝纤维化和需要肝移植的主要原因。在这篇综述中,作者强调了炎性小体在触发肝纤维化方面的间接和直接作用的不断增加的证据,以及抗纤维化治疗的潜在新靶点。